Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

January 2016

P&T Committee Updates


At the December 14, 2015 meeting, the Harvard Pilgrim Pharmacy & Therapeutics Committee reviewed three medications and decided the following.

P&T Committee Review and Decisions

Name

Description and Indication

Decision

Corlanor (ivabradine) 

Corlanor is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction = 35%, who are in sinus rhythm with resting heart rate = 70 beats per minute and either are on maximally tolerated doses of beta blockers or have a contraindication to beta blocker use. 

  • Added as a Preferred Brand to the Value and Medicare Advantage formularies with prior authorization and a quantity limit of 60 tablets per 30 days

  • Moved to Preferred Brand tier on the Premium formularies with prior authorization and a quantity limit of 60 tablets per 30 days

Entresto (sacubitril/valsartan) 

Entresto is a combination of sacubitril, a neprilysin inhibitor, and valsartan (Diovan), an angiotensin II receptor blocker, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.  

  • Added as a Preferred Brand to the Value and Medicare Advantage formularies with prior authorization and a quantity limit of 60 tablets per 30 days

  • Moved to Preferred Brand tier on the Premium formularies with prior authorization and a quantity limit of 60 tablets per 30 days

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Medicare Advantage Stride Provider Service Center Phone Number

Hospital and Ancillary Facilities: Tell Us How We’re Doing

New Cost Estimator Tool Coming to Maine

CLINICIAN CORNER

Smoking Cessation Treatment and Resources

Members’ Rights and Responsibilities

P&T Committee Updates

Specialty Pharmacy Program Updates

OFFICE ASSISTANT

2016 Fee Schedule Updates

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator